

# HR 1496

Beating Infections through Research and Development Act of 2007

Congress: 110 (2007–2009, Ended)

Chamber: House
Policy Area: Health
Introduced: Mar 13, 2007

Current Status: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Latest Action: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property. (Apr 20, 2007)

Official Text: https://www.congress.gov/bill/110th-congress/house-bill/1496

### **Sponsor**

Name: Rep. Baird, Brian [D-WA-3]

Party: Democratic • State: WA • Chamber: House

#### **Cosponsors** (4 total)

Cosponsor	Party / State	Role	<b>Date Joined</b>
Rep. Cubin, Barbara [R-WY-At Large]	$R \cdot WY$		Mar 13, 2007
Rep. Matheson, Jim [D-UT-2]	$D \cdot UT$		Mar 13, 2007
Rep. Carter, John R. [R-TX-31]	$R \cdot TX$		Jun 11, 2007
Rep. Ferguson, Mike [R-NJ-7]	$R \cdot NJ$		Sep 6, 2007

# **Committee Activity**

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 14, 2007
Judiciary Committee	House	Referred to	Apr 20, 2007
Ways and Means Committee	House	Referred To	Mar 13, 2007

### **Subjects & Policy Tags**

## **Policy Area:**

Health

#### **Related Bills**

No related bills are listed.

Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Establishes the Commission on Infectious Diseases Product Development to identify drug-resistant infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.

#### **Actions Timeline**

- Apr 20, 2007: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
- Mar 14, 2007: Referred to the Subcommittee on Health.
- Mar 13, 2007: Introduced in House
- Mar 13, 2007: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the
  Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for
  consideration of such provisions as fall within the jurisdiction of the committee concerned.